|
Online CME Activity
Suicide in Psychiatry: Risks and Treatments
|
NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
Suicide in Psychiatry: Risks and Treatments
1.00 AMA PRA Category 1 Credits™
Learning Objective
Based on recent research, examine risks of suicide associated with psychiatric disorders and the effects of specific types of treatments used for such disorders.
Accreditation
This educational program is conceived and credited in accordance with ACCME’s Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute’s Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 1.00 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Faculty and Editorial Board
Written By:
Ross Baldessarini, MD, Professor of Psychiatry, Harvard Medical School, Boston, Massachusetts
Edited By:
Christopher Drury, MA, Pri-Med Institute
Financial Disclosure Statement(s)
Dr Baldessarini is a consultant or research collaborator with Auritec; Biotrofix; IFI; Janssen, LP; JDS; Eli Lilly and Company; Merck & Co., Inc.; NeuroHealing; Novartis Pharmaceuticals Corporation; SK-BioPharmaceuticals; and Solvay Corporations. He is not a member of pharmaceutical speakers bureaus, nor does he or any family member hold equity positions in biomedical or pharmaceutical corporations.
Mr Drury has no financial relationships to disclose.
Commercial Support:
Pri-Med Institute, a grant from the Bruce J. Anderson Foundation and the McLean Private Donors Psychopharmacology Research Fund.
Pri-Med Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|
